British Columbia – Vancouver – Vancouver
Corporation
www.zalicus.com
British Columbia
Vancouver
Vancouver
Corporation
active
Zalicus utilizes its unique drug discovery and development capabilities to develop a pipeline of innovative therapies for the treatment of pain and inflammation. Our unique mix of powerful discovery technologies, novel clinical programs and experienced drug development professionals provide a solid foundation for success.
Zalicus Pipeline - Focused on pain and inflammation: Our mission is to create effective treatments for pain and inflammation. We focus our research and development resources on efficiently advancing programs in these core therapeutic areas.
Our pipeline includes Exalgoâ„¢ (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time, Synaviveâ„¢, in Phase 2 development for rheumatoid arthritis and our Ion channel program, which is advancing a lead candidate into clinical development for pain.
Expertise to develop innovative product candidates: Our expertise lies in advancing the discovery and development of differentiated product candidates through advanced screening and identification platforms. Zalicus draws on proprietary technology and a world-class scientific team to fuel a promising pipeline and enable the formation of valuable collaborations.
We apply our selective ion-channel modulation platform and our combination high throughput screening capabilities to discover innovative therapeutics for both our internal product pipeline and our collaborators.
Technology: Zalicus has two unique drug discovery platforms that fuel its future pipeline and enable additional revenue generating collaborations. Our industry leading Ion Channel platform allows us to identify candidates that harness the potential of the electrophysiology of calcium channel blockers for acute and chronic pain. Our proprietary cell-based combination High Throughput Screening (cHTS) technology evaluates the therapeutic potential of various drug combinations while elucidating new mechanisms to treat diseases.
Collaborators: Collaboration is an important component of Zalicus' business strategy. We form collaborations with pharmaceutical and biotechnology companies, as well as US government agencies, to support the development of select product candidates generated by our discovery technologies. Zalicus has multiple revenue-generating collaborations and continues to leverage its proprietary discovery technologies with ongoing research collaborations. Our drug discovery technology has identified Prednisporin, one of our most advanced clinical product candidates, on behalf of our partners at Fovea Pharmaceuticals (a division of Sanofi Aventis), and has also been seen as an important technology by our collaborators at Novartis in support of their oncology research efforts.
Country of Ownership: Canada
Year Established: 1995
Exporting: No
Primary Industry (NAICS): 325410 - Pharmaceutical and Medicine Manufacturing
Alternate Industries (NAICS): 414510 - Pharmaceuticals and Pharmacy Supplies Wholesaler-Distributors
541710 - Research and Development in the Physical, Engineering and Life Sciences
Primary Business Activity: Manufacturer / Processor / Producer
Products:
Pharmaceuticals
Corrigan Mark
Renz Justin
Snutch Terrance
No associations
LandOfFree
Zalicus Pharmaceuticals Ltd. does not yet have a rating. At this time, there are no reviews or comments for this company.
If you have personal experience with Zalicus Pharmaceuticals Ltd., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Zalicus Pharmaceuticals Ltd. will most certainly appreciate the feedback.
Profile ID: LFCA-COD-O-38696